Prof Tom John

Happy to share this paper from one of our #Swiss residents @PeterMacCC: Does IO given in #SCLC up front impact responses and survival in subsequent lines of therapy? Sadly the answer was no, chemo outcomes were similar to that seen pre-IO. Maybe BiTES? authors.elsevier.com/c/1lw8qcYZOi...

Looking forward to playing with @drsanjaypopat.bsky.social - a lot of fun rehearsing covers and @mayhemtomi tracks. Check us out tonight @iaslc.bsky.social #wclc2025

So much fun rehearsing some acoustic tunes with @drsanjaypopat.bsky.social - don’t forget to stick around after the #WCLC25 plenary tomorrow evening @iaslc.bsky.social

Looking forward to playing some tunes with my good friend and musician @drsanjaypopat.bsky.social tomorrow at #WCLC25. Make sure you stick around at the welcome reception Saturday evening!

Loving this @mayhemtomi track, a lovely collaboration with @dean_fennell on synths. Inspired by the “Pale blue dot speech” from Carl Sagan. Check it out on all streaming platforms details here: mayhemtom.com.au

Australia's deadliest cancer to get new screening program After years of lobbying from patients, the first ever national lung cancer screening program will roll out next month for people who have a significant history of smoking.

🙏🏽 ABC for shining the light on 🇦🇺 deadliest cancer. Bring on #lungcancer screening www.abc.net.au/news/2025-06... @abcnewsbot.bsky.social @gerryhanna.bsky.social @drtomjohn.bsky.social @dkarikios.bsky.social @bensolomon1.bsky.social

🇦🇺 guidelines for #lungcancer screening. Screening coming 1st July. Great step forward in #lungcancer Mx. Spread the word. www.health.gov.au/our-work/nlc... @newsgp.bsky.social @ausgov.bsky.social @drtomjohn.bsky.social @bensolomon1.bsky.social @dkarikios.bsky.social

Vaccines in Thoracic Oncology: The Next Frontier in Immunotherapy Conversations in Lung Cancer Research · Episode

If you’re interested in where #lungcancer vaccines are at relative to #melanoma, check out this @togaanz.bsky.social podcast with @gvlongphdmd.bsky.social and Ken OByrne.

podcasts.apple.com/au/podcast/v...

open.spotify.com/episode/0OJb...

Fantastic work to get this happening 🙌🏾🙌🏾🙌🏾

Clinician Scientist Fellowship - Parkville, Melbourne (AU) job with Peter MacCallum Cancer Centre – Parkville | 12839522 Peter Mac is launching Australia’s first clinician-scientist fellowship to advance cancer care, fostering innovation and global collaboration.

Australia completely lacks a dedicated training program for clinician scientists. With the vision and support of VMIAL
@petermaccc.bsky.social is extremely proud to announce the first clinician-scientist fellowship. If you meet the eligibility criteria PLEASE APPLY!
www.nature.com/naturecareer...

Atheistic Listen to content by Mayhemtom.

Close to releasing first single from new album. If you’re interested please presave it. Presaves help the #spotifyaunz and #applemusic algorithm figure out how hot a #indie #indiemusic track might be. gyro.to/Atheistic

🔥 @natmedicine.bsky.social 🆙
✅Molecular residual disease analysis of adj osimertinib in resected EGFR-mutated stage IB–IIIA NSCLC
🎯MRD preceded imaging DFS by a median of 4.7
🩸RaDaR MRD analysis
👥 Dr. Roy Herbst @drtomjohn.bsky.social
#LCSM @oncoalert.bsky.social
www.nature.com/articles/s41...

It’s in the paper. Median follow up time from randomisation was 44.2 months in Osi arm and 19.1 months in placebo. Median follow up post Osi was 11.7months

My concern with this is that CNS was a common site of recurrence and there is morbidity and mortality associated. Nuanced discussion with patient re: toxicity vs waiting. I suspect most of my pts would take Osi, but close surveillance also very reasonable.

Random chance from small numbers. But note that baseline is post surgery +/- chemo. More likely MRD+ if higher stage and also MRD+ effectively is St4, as on cessation of Osi, all MRD+ recurred

I think these data highlight the relevance of MRD assays in guiding treatment decisions esp in oncogene driven tumours. This may mean longer duration of therapy though.

MRD RaDaR assay was 65% sensitive and 95% specific. The co-mutation data are also interesting. TP53 seems to also be associated with poorer outcomes in early stage disease #NSCLC #Earlystage @petermaccc.bsky.social

In this study we found that very few pt developed MRD positivity on Osi, but on cessation of Osi 17% developed MRD+ and most within 12mo of stopping

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer - Nature Medicine Exploratory post hoc analysis of molecular residual disease from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer shows that mol...

Honoured to co-first author this important paper with Prof Herbst and the entire team looking at MRD in the ADAURA trial. www.nature.com/articles/s41...

Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survi... Bristol Myers Squibb (NYSE: BMY) today announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo ® (nivolumab) in combination with platinum-do...

Great day for lung cancer care!. Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! Just a press release for now but full data upcoming! #lcsm news.bms.com/news/corpora...

Non KRAS G12C mutations an important unmet need in lung cancer: we see them often, including in non-smokers

Nice work here highlighted by @drtomjohn.bsky.social

We hope to open 1L RMC-6236 trial at Chelsea & Westminster later this year

Congratulations to Adel from @petermac for this analysis showing KRAS G12D patients are more likely to be non-smokers but also associated with low PDL1, comutations with TP53/STK11 and derive limited immunotherapy response. Area of need for targeted Rx #LCSM smex-ctp.trendmicro.com/wis/clicktim...

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations The Kirsten rat sarcoma oncogene homolog (KRAS) is one of the most frequently mutated oncogenes in non-small-cell lung cancer (NSCLC), occurring in approximately 30 % of cases [1]. KRAS mutations are ...

*New Publication* led by Dr Adel Shahnam from @petermaccc.bsky.social in Lung Cancer

Poorer survival outcomes in patients with KRAS G12D mutations receiving immunotherapy.

Novel targeted therapies should be examined in detail for this population.

www.lungcancerjournal.info/article/S016...

#lcsm

Kamala Harris-Black history is American history. Our music, art, sports, literature, leadership, resistance, and resilience are fundamental to the fabric of our nation and the progress that we fight for. This month and every month, we celebrate Black history, and we continue our fight for justice and equality for every American.

We are seeing anti-medical, anti-science narratives everywhere – how can doctors like me respond? | Mariam Tokhi Medical practitioners are no longer trusted instinctively, with sometimes devastating consequences. How do we engage with people who mistrust us?

www.theguardian.com/commentisfre...

Thank you Professor! You and Jonathan Cebon were the inspiration and mentorship behind me getting here!

Yes it is the balance of OS benefit with AEs that will be critical. Then there is also the degree of benefit compared with FLAURA2 - where OS benefit has trended

Lovely day at the #pinktest #mcgrath day in #sydney, India vs Australia.

HIT IT WITH YOUR BEST SHOT 👊
Catch our latest podcast on IO in early-stage NSCLC in the Australian context.

Apple: https://buff.ly/3ZgBePP
Spotify: https://buff.ly/3Ze0I0c

Lung cancer is the leading cause of cancer death in women. Don't ignore the signs!

Thanks for coming on the journey with us this #LungCancerAwarenessMonth

Find out more > https://buff.ly/3YG2OWB
#LCAM